INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 410m ago
HOUSE PTR10m ago
SEC 13F10m ago
ROBINHOOD CHAIN9m ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Allan Jonathan sold STOK

GENERAL COUNSEL & CORP SEC · Stoke Therapeutics, Inc. · Common Stock

Side
SELL
Value
$292K
Shares
8,692
Price
$33.64
Executed
Mar 20, 2026
Disclosed
Mar 24, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Mar 20 executedMar 24, 2026 disclosed

STOK · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
27/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+15 / 25

    $292K reported value · 30.1% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 16 prior trades recorded in this security

  • Frequency & clustering+15 / 15

    3 other actors traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · STOK

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    TB
    Ticho BarryCHIEF MEDICAL OFFICER
    STOKStoke Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$185K
    6,995 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    TB
    Ticho BarryCHIEF MEDICAL OFFICER
    STOKStoke Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$5,398
    200 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    0
    AJ
    Allan JonathanGENERAL COUNSEL & CORP SEC
    STOKStoke Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$17K
    627 sh
    		Oct 2, 2026Oct 2, 2026
    traded Oct 2, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CA
    Cumbo AlexanderDirector
    STOKStoke Therapeutics, Inc.
    Grant or award
    		A—
    39.7K sh
    		Sep 23, 2026Sep 25, 2026
    traded Sep 23, 2026
    		+2dSEC FORM 4

    Evidence

    2
    AJ
    Allan JonathanGENERAL COUNSEL & CORP SEC
    STOKStoke Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$44K
    1,457 sh
    		Jun 16, 2026Jun 18, 2026
    traded Jun 16, 2026
    		+2dSEC FORM 4

    Evidence

    9
    KC
    Kahn ClareDirector
    STOKStoke Therapeutics, Inc.
    Grant or award
    		A—
    30.8K sh
    		Apr 3, 2026Apr 7, 2026
    traded Apr 3, 2026
    		+4dSEC FORM 4

    Evidence

    13
    AJ
    Allan JonathanGENERAL COUNSEL & CORP SEC
    STOKStoke Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$21K
    601 sh
    		Mar 20, 2026Mar 24, 2026
    traded Mar 20, 2026
    		+4dSEC FORM 4

    Evidence

    32
    HJ
    Hoitt JasonChief Patient Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$4,419
    139 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    40
    LT
    Leggett ThomasChief Financial Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$31K
    922 sh
    		Mar 17, 2026Mar 19, 2026
    traded Mar 17, 2026
    		+2dSEC FORM 4

    Evidence

    39
    HJ
    Hoitt JasonChief Patient Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$55K
    1,762 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    32
    LT
    Leggett ThomasChief Financial Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$5,468
    172 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    40
    HJ
    Hoitt JasonChief Patient Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$34K
    1,033 sh
    		Mar 17, 2026Mar 19, 2026
    traded Mar 17, 2026
    		+2dSEC FORM 4

    Evidence

    32
    LT
    Leggett ThomasChief Financial Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$1,215
    37 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    39
    LT
    Leggett ThomasChief Financial Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$68K
    2,173 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    40
    HJ
    Hoitt JasonChief Patient Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$25K
    748 sh
    		Mar 17, 2026Mar 19, 2026
    traded Mar 17, 2026
    		+2dSEC FORM 4

    Evidence

    32
    HJ
    Hoitt JasonChief Patient Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$986
    30 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    40
    LT
    Leggett ThomasChief Financial Officer
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$42K
    1,274 sh
    		Mar 17, 2026Mar 19, 2026
    traded Mar 17, 2026
    		+2dSEC FORM 4

    Evidence

    36
    AJ
    Allan JonathanGENERAL COUNSEL & CORP SEC
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$81K
    2,476 sh
    		Mar 17, 2026Mar 19, 2026
    traded Mar 17, 2026
    		+2dSEC FORM 4

    Evidence

    36
    AJ
    Allan JonathanGENERAL COUNSEL & CORP SEC
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$60K
    1,791 sh
    		Mar 17, 2026Mar 19, 2026
    traded Mar 17, 2026
    		+2dSEC FORM 4

    Evidence

    36
    AJ
    Allan JonathanGENERAL COUNSEL & CORP SEC
    STOKStoke Therapeutics, Inc.
    Open-market sale
    		SELL$132K
    4,222 sh
    		Mar 18, 2026Mar 19, 2026
    traded Mar 18, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001966716-26-000008
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 20, 2026
    Published
    Mar 24, 2026
    Ingested by INSIDER
    Nov 5, 04:09 UTC
    Last re-read
    Nov 5, 04:09 UTC

    Extracted facts

    Filer
    Allan Jonathan
    Role
    GENERAL COUNSEL & CORP SEC
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Stoke Therapeutics, Inc.
    Ticker
    STOK
    Shares
    8,692
    Price per share
    $33.64
    Value
    $292,359
    Execution date (reported)
    Mar 20, 2026
    Owned after transaction
    20.1K shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 8,692
    • Price: $33.6354

    = $292,359

    What this establishes

    Allan Jonathan filed this Form 4 reporting a open-market sale of STOK on Mar 20, 2026. It became public on Mar 24, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    GENERAL COUNSEL & CORP SEC
    Allan Jonathancik:0001966716
    Issuer
    Stoke Therapeutics, Inc.cik:0001623526

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.